Mourad A. M. Aboul‐Soud; Alhusain J. Alzahrani; Amer Mahmoud · 2021 · Cells
Paper
The discovery of induced pluripotent stem cells (iPSCs) has made an invaluable contribution to the field of regenerative medicine, paving way for identifying the true potential of human embryonic stem cells (ESCs). Since the controversy around ethicality of ESCs continue to be debated, iPSCs have been used to circumvent the process around destruction of the human embryo. The use of iPSCs have transformed biological research, wherein increasing number of studies are documenting nuclear reprogramming strategies to make them beneficial models for drug screening as well as disease modelling. The flexibility around the use of iPSCs include compatibility to non-invasive harvesting, and ability to source from patients with rare diseases. iPSCs have been widely used in cardiac disease modelling, studying inherited arrhythmias, neural disorders including Alzheimer's disease, liver disease, and spinal cord injury. Extensive research around identifying factors that are involved in maintaining the identity of ESCs during induction of pluripotency in somatic cells is undertaken. The focus of the current review is to detail all the clinical translation research around iPSCs and the strength of its ever-growing potential in the clinical space.
Analysis
This review details the clinical translation research and potential of induced pluripotent stem cells (iPSCs) in regenerative therapies, disease modeling, and drug screening.
Discovery
Hany E. Marei
Wenzhao Cheng; Yiming Zeng; Dachun Wang
Chenxia Hu; Lingfei Zhao; Lingjian Zhang; Qiongling Bao; Lanjuan Li
Sharif Moradi; Hamid Mahdizadeh; Tomo Šarić; Johnny Kim; Javad Harati; Hosein Shahsavarani; Boris Greber; Joseph B. Moore
Yu Han; Xuezhou Li; Yanbo Zhang; Yanbo Zhang; Yuping Han; Jianxun Ding
Barbara Łukomska; Luiza Stanaszek; Ewa Zuba‐Surma; Paweł Łęgosz; Sylwia Sarzyńska; Katarzyna Drela
Source record